Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 214 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cymbalta Clear all
Completed Phase 3 Interventional Results available

Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome

NCT00114127
View directory record Official record
Conditions
Anxiety Disorder
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 30, 2026, 8:27 PM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 3 Interventional

Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression

NCT00042562
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
23
States / cities
Carlsbad, California • Los Angeles, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 30, 2026, 8:27 PM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence

NCT00190606
View directory record Official record
Conditions
Urinary Stress Incontinence
Interventions
Duloxetine, Pelvic Floor Muscle Training (PFMT), Imitation PFMT, placebo
Drug · Procedure
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

NCT00507936
View directory record Official record
Conditions
Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy, Neuralgia, Diabetic
Interventions
ABT-894, placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 4 Interventional Results available

Treating Hearing Loss to Improve Mood and Cognition in Older Adults

NCT03321006
View directory record Official record
Conditions
Hearing Loss, Depression
Interventions
Phonak Audeo B-R 90 hearing aid device (Active), Duloxetine or escitalopram, Audeo B-R 90 hearing aid device (Sham)
Device · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 30, 2026, 8:27 PM EDT
Recruiting Phase 4 Interventional

Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures

NCT05851898
View directory record Official record
Conditions
Depression in Old Age, Fragility Fracture
Interventions
Duloxetine 30 mg
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

NCT00854100
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 4 Interventional Results available

An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome

NCT00401258
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
duloxetine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 4 Interventional

Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)

NCT00479726
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 28, 2007 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 3 Interventional

Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder

NCT00122824
View directory record Official record
Conditions
Anxiety Disorders
Interventions
duloxetine hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 30, 2026, 8:27 PM EDT
Withdrawn Not applicable Interventional

A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain

NCT02578459
View directory record Official record
Conditions
Pain Management, Cancer Pain
Interventions
Intrathecal Drug Delivery System, Conventional Medical Management
Device · Other
Lead sponsor
Flowonix Medical
Industry
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 3 Interventional

A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

NCT00122850
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Duloxetine, venlafaxine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
19
States / cities
Birmingham, Alabama • La Mesa, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 4 Interventional Results available

Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?

NCT02005601
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Placebo, Duloxetine 60mg
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
25 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)

NCT00386243
View directory record Official record
Conditions
Low Back Pain, Pain, Pain, Intractable
Interventions
Cognitive behavioral therapy, Pain self-management program, Co-Analgesic Therapy, Opioid Analgesics
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 30, 2026, 8:27 PM EDT
Recruiting Phase 2 Interventional

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

NCT06614322
View directory record Official record
Conditions
Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
Interventions
Pregabalin, Duloxetine, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics

NCT00742573
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressants through Texas Medication Algorithm (TMA), Brief Interpersonal Psychotherapy (IPT-B)
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01369095
View directory record Official record
Conditions
Depression
Interventions
Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
48
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 30, 2026, 8:27 PM EDT
Not listed Phase 4 Interventional

Cymbalta for Depression as a Complication of Bereavement

NCT00658931
View directory record Official record
Conditions
Depression, Bereavement
Interventions
Drug treatment with Cymbalta
Drug
Lead sponsor
Jefferson Clinic, P.C.
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 12, 2010 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 4 Interventional Results available

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

NCT01077375
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Sacramento, California • Cromwell, Connecticut • Danbury, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression

NCT00042575
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
9
States / cities
Trumbull, Connecticut • Lafayette, Indiana • Gaithersburg, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 30, 2026, 8:27 PM EDT
Recruiting Phase 4 Interventional

Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities

NCT06997198
View directory record Official record
Conditions
Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions
Deutetrabenazine Oral Capsule
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 30, 2026, 8:27 PM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 8:27 PM EDT